CytomX Therapeutics Company Profile (NASDAQ:CTMX)

About CytomX Therapeutics

CytomX Therapeutics logoCytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CTMX
  • CUSIP:
Key Metrics:
  • Previous Close: $15.64
  • 50 Day Moving Average: $12.72
  • 200 Day Moving Average: $11.72
  • 52-Week Range: $36,288,000.00 - $9.01
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.69
  • P/E Growth: -0.79
  • Market Cap: $567.54M
  • Outstanding Shares: 36,288,000
Profitability:
  • Net Margins: -579.42%
  • Return on Equity: -91.59%
  • Return on Assets: -29.72%
Debt:
  • Current Ratio: 8.98%
  • Quick Ratio: 8.98%
Additional Links:
Companies Related to CytomX Therapeutics:

Analyst Ratings

Consensus Ratings for CytomX Therapeutics (NASDAQ:CTMX) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $20.33 (30.01% upside)

Analysts' Ratings History for CytomX Therapeutics (NASDAQ:CTMX)
Show:
DateFirmActionRatingPrice TargetDetails
5/10/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
3/16/2016Jefferies GroupReiterated RatingBuy$19.00View Rating Details
1/20/2016Cowen and CompanyReiterated RatingBuyView Rating Details
11/2/2015Bank of America Corp.Initiated CoverageBuy$20.00View Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for CytomX Therapeutics (NASDAQ:CTMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2016        
8/3/2016Q2($0.41)($0.39)ViewN/AView Earnings Details
5/6/2016($0.26)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytomX Therapeutics (NASDAQ:CTMX)
Current Year EPS Consensus Estimate: $-1.59 EPS
Next Year EPS Consensus Estimate: $-1.80 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.11)($0.25)
Q2 20162($0.44)($0.32)($0.38)
Q3 20162($0.42)($0.33)($0.38)
Q4 20162($0.43)($0.35)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for CytomX Therapeutics (NASDAQ:CTMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for CytomX Therapeutics (NASDAQ:CTMX)
Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 51.95%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/10/2016Timothy M ShannonDirectorSell48,427$10.07$487,659.89View SEC Filing  
6/7/2016Ix L.P. CanaanDirectorSell111,498$10.01$1,116,094.98View SEC Filing  
6/3/2016Ix L.P. CanaanDirectorSell59,621$10.80$643,906.80View SEC Filing  
6/1/2016Ix L.P. CanaanDirectorSell22,463$10.75$241,477.25View SEC Filing  
5/27/2016Ix L.P. CanaanDirectorSell25,082$10.60$265,869.20View SEC Filing  
5/26/2016Timothy M ShannonDirectorSell51,343$10.34$530,886.62View SEC Filing  
5/24/2016Ix L.P. CanaanDirectorSell13,253$10.09$133,722.77View SEC Filing  
5/20/2016Ix L.P. CanaanDirectorSell8,687$10.10$87,738.70View SEC Filing  
10/14/2015Cynthia J LaddVPBuy3,000$12.00$36,000.00View SEC Filing  
10/14/2015Frederick W GluckDirectorBuy15,000$12.00$180,000.00View SEC Filing  
10/14/2015James E FlynnInsiderBuy625,000$12.00$7,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for CytomX Therapeutics (NASDAQ:CTMX)
DateHeadline
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : September 23, 2016 (NASDAQ:CTMX)
www.capitalcube.com - September 23 at 4:15 PM
News IconCanaan Partners Adds Joydeep Bhattacharyya and Rich Boyle As Partners (NASDAQ:CTMX)
www.finsmes.com - September 21 at 5:01 PM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : September 12, 2016 (NASDAQ:CTMX)
www.capitalcube.com - September 12 at 4:17 PM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : August 23, 2016 (NASDAQ:CTMX)
www.capitalcube.com - August 23 at 4:36 PM
capitalcube.com logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:CTMX)
www.capitalcube.com - August 10 at 4:36 PM
sg.finance.yahoo.com logoCytomX Therapeutics reports 2Q loss (NASDAQ:CTMX)
sg.finance.yahoo.com - August 3 at 10:07 PM
publicnow.com logoCytomX Announces Second Quarter 2016 Financial Results (NASDAQ:CTMX)
www.publicnow.com - August 3 at 4:35 PM
biz.yahoo.com logoQ2 2016 CytomX Therapeutics Inc Earnings Release - After Market Close (NASDAQ:CTMX)
biz.yahoo.com - August 3 at 9:57 AM
finance.yahoo.com logoCytomX Therapeutics to Announce Second Quarter 2016 Financial Results and Provide Mid-Year Update (NASDAQ:CTMX)
finance.yahoo.com - July 27 at 4:30 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : July 27, 2016 (NASDAQ:CTMX)
www.capitalcube.com - July 27 at 8:15 AM
capitalcube.com logoCytomX Therapeutics, Inc. – Value Analysis (NASDAQ:CTMX) : July 18, 2016 (NASDAQ:CTMX)
www.capitalcube.com - July 18 at 3:38 PM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CTMX-US : July 11, 2016 (NASDAQ:CTMX)
www.capitalcube.com - July 11 at 8:04 AM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a V (NASDAQ:CTMX)
biz.yahoo.com - June 13 at 4:06 PM
publicnow.com logoCytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors (NASDAQ:CTMX)
www.publicnow.com - June 13 at 8:19 AM
capitalcube.com logoCytomX Therapeutics, Inc. :CTMX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 (NASDAQ:CTMX)
www.capitalcube.com - June 1 at 12:30 PM
News IconAre Analysts Bearish CytomX Therapeutics Inc (NASDAQ:CTMX) After Last Week? - Wall Street Hints and News (NASDAQ:CTMX)
hintsnewsnetwork.com - May 27 at 2:39 PM
News IconEarnings Review and Stock Rundown for CytomX Therapeutics Inc (NASDAQ:CTMX) - Wall Street Hints and News (NASDAQ:CTMX)
hintsnewsnetwork.com - May 26 at 1:43 PM
4-traders.com logoCytomX Therapeutics : to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:CTMX)
www.4-traders.com - May 26 at 1:43 PM
publicnow.com logoCytomX to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:CTMX)
www.publicnow.com - May 24 at 8:16 AM
fidaily.com logoCytomX Therapeutics, Inc. (CTMX) Investment Down in Latest Report from Deerfield Management Co - Finance Daily (NASDAQ:CTMX)
www.fidaily.com - May 18 at 11:56 AM
tradecalls.org logoRevenue Update on CytomX Therapeutics Inc(NASDAQ:CTMX) - Trade Calls (NASDAQ:CTMX)
www.tradecalls.org - May 18 at 11:56 AM
News IconCytomX Therapeutics, Inc. (NASDAQ:CTMX) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:CTMX)
www.sharetrading.news - May 16 at 11:46 AM
News IconCytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.24% After Short Covering - Wall Street Hints and News (NASDAQ:CTMX)
hintsnewsnetwork.com - May 14 at 11:41 AM
finance.yahoo.com logoCYTOMX THERAPEUTICS, INC. Financials (NASDAQ:CTMX)
finance.yahoo.com - May 13 at 1:04 PM
thestreet.com logoCytomX Therapeutics is Now Oversold (CTMX) (NASDAQ:CTMX)
www.thestreet.com - May 13 at 11:35 AM
News IconConsensus Rating Review for CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential (NASDAQ:CTMX)
www.bodyconfidential.com - May 11 at 11:41 AM
uk.finance.yahoo.com logoCytomX Therapeutics reports 1Q loss - Yahoo Finance UK (NASDAQ:CTMX)
uk.finance.yahoo.com - May 7 at 11:24 AM
News IconEarnings Outlook on CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential (NASDAQ:CTMX)
www.bodyconfidential.com - May 7 at 11:24 AM
publicnow.com logoCytomX Announces First Quarter 2016 Financial Results (NASDAQ:CTMX)
www.publicnow.com - May 6 at 7:14 AM
sg.finance.yahoo.com logoCytomX Therapeutics reports 1Q loss (NASDAQ:CTMX)
sg.finance.yahoo.com - May 6 at 7:10 AM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:CTMX)
biz.yahoo.com - May 6 at 7:03 AM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CTMX)
biz.yahoo.com - May 6 at 7:03 AM
News IconThis Weeks Broker Price Targets For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Share Trading News (NASDAQ:CTMX)
www.sharetrading.news - May 3 at 11:27 AM
News IconShare Performance and Target Price Review CytomX Therapeutics Inc (NASDAQ:CTMX) - B.O.D.Y Confidential (NASDAQ:CTMX)
www.bodyconfidential.com - April 30 at 11:32 AM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CTMX)
biz.yahoo.com - April 28 at 4:10 PM
capitalcube.com logoETF’s with exposure to CytomX Therapeutics, Inc. : April 28, 2016 (NASDAQ:CTMX)
www.capitalcube.com - April 28 at 1:11 PM
News IconCytomX Therapeutics, Inc. (NASDAQ:CTMX) Latest Broker Views - Risers & Fallers (NASDAQ:CTMX)
www.risersandfallers.com - April 27 at 11:58 AM
capitalcube.com logoCytomX Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CTMX-US : April 27, 2016 (NASDAQ:CTMX)
www.capitalcube.com - April 27 at 8:27 AM
cchdailynews.com logoCytomx Therapeutics Incorporated (NASDAQ:CTMX) Shorts Decreased by 3.22% After Short Covering - CCH Daily News (NASDAQ:CTMX)
cchdailynews.com - April 26 at 12:00 PM
News IconCytomX Therapeutics Inc (NASDAQ:CTMX) Share Rating Recap - B.O.D.Y Confidential (NASDAQ:CTMX)
www.bodyconfidential.com - April 26 at 12:00 PM
publicnow.com logoCytomX to Present at the 2016 Bank of America Merrill Lynch Healthcare Conference (NASDAQ:CTMX)
www.publicnow.com - April 26 at 8:38 AM
News IconCytomX Therapeutics, Inc. (NASDAQ:CTMX) Updated Broker Ratings - Risers & Fallers (NASDAQ:CTMX)
www.risersandfallers.com - April 22 at 12:04 PM
News IconCompany Update (NYSE:ABBV): AbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates (NASDAQ:CTMX)
jutiagroup.com - April 22 at 12:04 PM
biz.yahoo.com logoCytomX AbbVie Probody Drug Conjugates Collaboration Call scheduled for 5:00 pm ET today (NASDAQ:CTMX)
biz.yahoo.com - April 21 at 5:00 PM
publicnow.com logoCytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates (NASDAQ:CTMX)
www.publicnow.com - April 21 at 4:21 PM
biz.yahoo.com logoCYTOMX THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, F (NASDAQ:CTMX)
biz.yahoo.com - April 21 at 4:13 PM
finance.yahoo.com logoAbbVie and CytomX Announce Strategic Collaboration for Probody Drug Conjugates (NASDAQ:CTMX)
finance.yahoo.com - April 21 at 4:01 PM
News IconBroker Roundup For CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Share Trading News (NASDAQ:CTMX)
www.sharetrading.news - April 20 at 11:35 AM
clintongazette.com logoCytomX Therapeutics Inc (NASDAQ:CTMX) Analyst Rating Review - Clinton Financial (NASDAQ:CTMX)
www.clintongazette.com - April 18 at 11:39 AM
clintongazette.com logoCytomx Therapeutics Incorporated (NASDAQ:CTMX) Sellers Covered 3.22% of Their Shorts - Clinton Financial (NASDAQ:CTMX)
www.clintongazette.com - April 16 at 11:11 AM

Social

CytomX Therapeutics (NASDAQ:CTMX) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff